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Ara h: Arachis hypogaea
BAT: Basophil activation test
CD-sens: Allergen threshold sensitivity
fMLP: Formyl-methionyl-leucylphenylalanine
LEAP: Learning Early about Peanut Allergy
LEAP-On: Persistence of Oral Tolerance to Peanut
OFC: Oral food challenge
PA: Peanut allergy
PAS: Peanut Allergy Sensitization
rAra h: Recombinant Arachis hypogaea
SPT: Skin prick test
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standard to assess peanut allergy (PA), but it involves a risk of
allergic reactions of unpredictable severity.
Objective: Our aim was to identify biomarkers for risk of severe
reactions or low dose threshold during OFC to peanut.
Methods: We assessed Learning Early about Peanut Allergy
study, Persistance of Oral Tolerance to Peanut study, and
Peanut Allergy Sensitization study participants by
administering the basophil activation test (BAT) and the skin
prick test (SPT) and measuring the levels of peanut-specific IgE,
Arachis hypogaea 2–specific IgE, and peanut-specific IgG4, and
we analyzed the utility of the different biomarkers in relation to
PA status, severity, and threshold dose of allergic reactions to
peanut during OFC.
Results: When a previously defined optimal cutoff was used, the
BAT diagnosed PAwith 98% specificity and 75% sensitivity. The
BAT identified severe reactions with 97% specificity and 100%
sensitivity. The SPT, level of Arachis hypogaea 2–specific IgE,
level of peanut-specific IgE, and IgG4/IgE ratio also had 100%
sensitivity but slightly lower specificity (92%, 93%, 90%, and
88%, respectively) to predict severity. Participants with lower
thresholds of reactivity had higher basophil activation to peanut
in vitro. The SPT and the BAT were the best individual
predictors of threshold. Multivariate models were superior to
individual biomarkers and were used to generate nomograms to
calculate the probability of serious adverse events during OFC
for individual patients.
Conclusions: The BAT diagnosed PA with high specificity and
identified severe reactors and low threshold with high specificity
and high sensitivity. The BAT was the best biomarker for
severity, surpassed only by the SPT in predicting threshold.
Nomograms can help estimate the likelihood of severe reactions
and reactions to a low dose of allergen in individual patients
with PA. (J Allergy Clin Immunol 2020;146:344-55.)
Key words: Basophil, basophil activation test, diagnosis, food al-
lergy, LEAP study, peanut allergy, severity, threshold, adverse events
Oral food challenge (OFC) is the criterion standard to diagnose
and assess resolution of food allergies. OFC is also the criterion
standard to confirm the eligibility of patients with food allergy for
clinical trials of experimental treatments for food allergy and to
assess patients’ clinical responses to such treatments. OFC can
result in potentially severe allergic reactions and requires an
experienced and highly skilled clinical team with the ability and
equipment needed to treat anaphylaxis. Although rare, 2 deaths
have been reported in children undergoing OFC.1,2 A biomarker
that could identify individuals at high-risk for severe allergic re-
actions and/or for reacting to small amounts of the allergens
would ensure patients’ safety and comfort and improve current
management of patients with food allergy.
Peanut is one of the main culprits of fatal and near-fatal food-
induced allergic reactions.3 The prevalence of peanut allergy (PA)
is increasing, and some studies have reported an increase in food-
induced anaphylaxis fatalities.4 Evidence about the utility of the
skin prick test (SPT) and specific IgE level to predict the severity
of allergic reactions to peanut is conflicting.5-8 Arachis hypogaea
2 (Ara h 2)-specific IgE is a discriminativemarker to diagnose PA,
and an association with severity has been observed.9,10 The baso-
phil activation test (BAT) has shown the highest accuracy fordiagnosing PA, with a higher proportion of activated basophils
(as measured by percentage of CD631 basophils) being associ-
ated with more severe allergic reactions during OFC9,11,12 and
the cumulative threshold dose being associated with the concen-
tration at which the basophils reacted in vitro.9,13 Despite the need
for fresh blood samples and the existence of a subset of individ-
uals with nonresponder basophils, the BAT has emerged as a
promising biomarker to identify high-risk patients with PA.
The Learning Early about Peanut Allergy (LEAP) study14
conferred a unique opportunity to perform the BATand other tests
in a large number of well-characterized children who were being
assessed for PA. We aimed to assess their utility in diagnosing PA
and in predicting severity and threshold dose of allergic reactions
during oral peanut challenges in this and related cohorts.METHODS
Study cohorts
Participants in the LEAP,15 Persistence of Oral Tolerance to Peanut (LEAP-
On),16 and PA Sensitization (PAS) studies were included (see Table E1 in this
article’s Online Repository at www.jacionline.org). The LEAP study was a
large interventional study that assessed the effect of early peanut consumption
on the development of PA by age 5 years.15 The LEAP study participants
(groups II and III of the LEAP screening study14) were followed up after 1
year of peanut avoidance in the LEAP-On study.16 Children who had been
excluded from the LEAP study as infants were included in the PAS study.14
An additional cohort of children recruited from specialized paediatric allergy
clinics in London9 was included for external validation (see Table E2 in this
article’s Online Repository at www.jacionline.org). All studies were approved
by the relevant Research Ethics Committees in the United Kingdom (reference
numbers 04/Q0403/13 [LEAP study], 10/H0711/77 [LEAP-On study], 11/LO/
0045 [PAS study], and 10/H0802/044 [clinic cohort]).
We aimed to perform the BAT in LEAP study participants who showed
evidence of peanut sensitization at any time point in the LEAP study on either
the SPT (>_1 mm) or serum level of specific IgE (>_0.10 kU/L) to peanut and in
50 LEAP study participants who showed a peanut SPT result of 0 mm and a
specific level of IgE to peanut less than 0.1 kU/L at all time points of the study
before their assessment.We aimed to repeat the BAT to peanut at the end of the
LEAP-On study in the same participants. In the PAS study, we aimed to test all
participants who were assessed at approximately 60 months of age.14
Skin prick testing and determination of IgE and
IgG4 levels
The SPTandBATwere performed on the same day as OFC. Peanut-specific
IgE and IgG4 levels were determined by using samples collected when blood
was collected for the BAT. Skin prick testing was performed by using a
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previously described.15 The levels of specific IgE to peanut and the peanut al-
lergens recombinant Arachis hypogaea (rAra h) 1, rAra h 2, rAra h 3, rAra h 8,
and rAra h 9 and the levels of peanut-specific IgG4 in the serum were
measured by using an immunoenzymatic assay (ImmunoCAP, ThermoFisher,
Uppsala, Sweden).BAT
Whole blood was collected into lithium heparin tubes and used to
perform the BAT to peanut extract on the same day and within 4 hours of
blood collection, as previously described.11 Briefly, 100 mL of whole blood
was incubated with the same volume of peanut extract (ALK-Abello)
diluted in RPMI medium (GIBCO, Paisley, United Kingdom), anti-IgE (1
mg/ml, Sigma-Aldrich, Poole, United Kingdom), anti-FceRI (2.5 mg/mL,
eBioscience, San Diego, Calif), formyl-methionyl-leucylphenylalanine
(fMLP) (1 mM [Sigma-Aldrich]), or RPMI medium alone. Cells were
stained with CD123-FITC (eBioscience, San Diego, Calif), CD203c-PE,
HLA-DR-PerCP, and CD63-allophycocyanin (Biolegend, San Diego,
Calif). Flow cytometry was performed by using FACS CantoII with FACS-
Diva software (BD Biosciences, San Jose, Calif). A mininum of 500 baso-
phils were acquired. The flow cytometry data were analyzed by using
FlowJo software (version 7.6.1 [TreeStar, Ashland, Ore]). Basophils were
gated as SSClow/CD203c1/CD1231/HLA-DR–.11,17 Basophil activation
was expressed as percentage of CD631 basophils. Individuals with nonre-
sponder basophils were defined as having a percentage of CD631 basophils
less than 5% to both IgE-mediated positive controls (anti-IgE and anti-
FcεRI) and were excluded from statistical analyses. Allergen threshold
sensitivity (CD-sens) was calculated for each BAT by estimating the param-
eters of a logistic growth function, one of which is the reciprocal of
CD-sens, by using a nonlinear model (see Fig E1 in this article’s Online
Repository at www.jacionline.org).Oral peanut challenges
Oral peanut challenges were performed according to the LEAP study
protocol as previously reported.15,16 Participants who were not IgE-sensitized
to peanut and had no history of reaction to peanut, no diagnosis of or suspected
allergy to sesame or tree nuts, and no history of anaphylaxis underwent open
challenge with a cumulative dose of up to 5 g of peanut protein given as a sin-
gle dose. Open challenge is the criterion standard to confirm peanut tolerance,
and all open challenges were indeed negative for PA. All other participants un-
derwent a double-blind, placebo-controlled peanut challenge to a cumulative
dose of up to 9.35 g of peanut protein given as incremental doses (see Table E3
in this article’s Online Repository at www.jacionline.org). Participants with
suspected PA, a history of life-threatening food-induced anaphylaxis, or an
SPT result of 7 mm or larger received an additional lower starting active
dose of 0.033 g of peanut protein. Some doses may have been repeated at
the discretion of the investigator performing OFC. The challenge was consid-
ered positive only when objective signs of an allergic reaction developed (see
Table E4 in this article’s Online Repository at www.jacionline.org), and the
symptoms were treated according to local guidelines, which follow the UK
Resuscitation Council recommendation to administer epinephrine to patients
with life-threatening airway (swelling, hoarseness, stridor) and/or breathing
(tachypnoea, wheeze, fatigue, cyanosis, specific oxygen saturation as
measured by pulse oximetry reading less than 90%, confusion) and/or circu-
lation (pale, clammy, hypotension, faintness, drowsiness, coma) problems.18
For participants for whom the outcome of OFC was inconclusive or not avail-
able, PAwas assessed by a diagnostic algorithm using the SPTand level of spe-
cific IgE to peanut. The procedure for OFC in the cohort used for external
validation was similar to that already described for the majority of study sub-
jects and was previously published.11
The severity of allergic reactions during OFC were classified according to
different severity scores represented inTableE5 (available in this article’sOnline
Repository at www.jacionline.org).19,20 The threshold dose was determined as
the cumulative amount of peanut protein (in grams) tolerated during OFC. The
cumulative tolerated dose was set to 9.35 g for all participants who passed OFC.Statistical analyses
Continuous variables were summarized by quantiles, and categorical
variables were summarized by counts and percentages. Comparisons of
continuous predictors use either the Student t-test or the Wilcoxon rank
sum-test. Receiver operator characteristic curve analyses were performed
to assess the diagnostic performance of each individual biomarker to predict
severe reactions. The performance of the optimal cutoffs was described by
using sensitivity, specificity, positive predictive value, and negative predic-
tive value.
CD-sens, the reciprocal of median effective dose, was estimated by fitting a
hierarchical Bayesian nonlinear model (see Fig E1) to the BAT curve for each
sample. This model assumes that each BAT curve follows the form of a 3-
parameter logistic growth curve. The resulting logistic curve midpoint param-
eter estimates from this model were used to estimate CD-sens. Model fitting
was performed by using the Markov chain Monte Carlo method, which was
performed by using the Stan software.21
Proportional odds logistic regression models were created for prediction
of reaction severity. The predictors used in these models were chosen on
the basis of being established predictors of reaction to peanut, and no
further variable selection was done on the basis of tests of statistical
hypotheses. Model performance was described by using bootstrap bias-
corrected concordance probabilities (C-statistics) and calibration accuracy
measurements (mean absolute prediction error and 90th percentile of
absolute prediction error). External model validation was done by using
data available from participants in a separate clinic cohort (see Table E2).
Statistical analysis was done in R software (version 3.5.2) and JMP Pro
(version 14). Data sets are available through TrialShare, a public website
managed by the Immune Tolerance Network (https://www.itntrialshare.
org/LEAP_JACI_BAT.url).RESULTS
Study population
There were 468 individual subjects enrolled across the LEAP,
LEAP-On, and PAS studies, and from these the BAT was
performed in 706 blood samples (335 from LEAP study
participants, 295 from LEAP-On study participants, and 76
from PAS study participants) on the day of the study visits at
which allergic status to peanut was assessed (Table I18 and see
Table E6 in this article’s Online Repository at www.jacionline.
org). An additional 123 subjects were eligible for the BAT but
were not tested for logistic reasons (see Tables E7 and E8 in
this article’s Online Repository at www.jacionline.org). On the
BAT, in 93 samples (13.1%) basophils did not react to the IgE-
mediated positive controls and were excluded from statistical an-
alyses. The excluded samples included those from 11 subjects
who were allergic to peanut (10.8% of nonresponders had PA,
and 6.7% of those with PA were nonresponders); also excluded
were 5 samples whose response status could not be determined
on account of missing data. Subjects with undetectable
peanut-specific IgE (<0.10 kU/L) who were not tested on the
BAT (n 5 373) were imputed to have a BAT result of 0 because
all patients with undetectable IgE had negative a BAT result in
both this and previous studies.11 A total of 981 cases with
performed or imputed BAT results were available for building
predictive models, and 558 independent samples from the
LEAP and PAS studies were used for all other analyses. In all,
14% percent of patients were allergic to peanut. The threshold
cumulative dose ranged between 0 and 10.1 g of peanut protein
(between 5 and 10.1 g in participants without allergy and between
0 and 4.5 g in participants with allergy, respectively). The cumu-
lative dose exceeded 9.35 g in participants who were given repeat
doses at the discretion of the investigators. According to the
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Atopic
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42/248 (17%) 7/221 (3%) 49/469 (10%) 26/202 (13%) 7/200 (4%) 33/402 (8%) 0 (0%) 34/42 (81%) 1 (33%) 35/81 (43%)
Ewan & Clark
grade severe
12/41 (29%) 2/7 (29%) 14/48 (29%) 1/25 (4%) 1/7 (14%) 2/32 (6%) (n 5 0) 8/32 (25%) 0/1 (0%) 8/33 (24%)
Medication grade
severe
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CTCAE grade
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CTCAE, Common Terminology Criteria for Adverse Events; OFC, oral food challenge.18
*Eczema based on SCORAD score of more than 0.
Median [interquartile range].
FIG 1. Mean basophil activation measured as percentage of CD63-positive (%CD631) basophils corrected
for spontaneous activation (ie, minus %CD631 basophils in the absence of in vitro stimulation) in response
to increasing concentrations of peanut extract in LEAP, LEAP-On, and PAS study participants by allergic sta-
tus. The BAT and allergic status were determined when subjects were approximately 5 years of age in the
LEAP and PAS studies and approximately 6 years of age in the LEAP-On study. Each regression line repre-
sents a smoothed mean dose response curve using a cubic spline with 95% bootstrapped CIs for each com-
bination of allergic status and reaction severity group.
J ALLERGY CLIN IMMUNOL
VOLUME 146, NUMBER 2
SANTOS ET AL 347
FIG 2. Basophil activation to peanut in participants with PA versus in participants without PA (median5 58.1
[interquartile range5 51.2-74.2] vsmedian5 10.3 [interquartile range5 1.9-24.2], respectively; P < .001) in the
PAS and LEAP studies (A) and receiver operator characteristic curve for the BAT and other biomarkers to
identify LEAP and PAS study subjects at high-risk of developing severe or life-threatening reactions during
OFCs, using the Common Terminology Criteria for Adverse Events score (B), Ewan and Clark grading (C),
or medication grading (D). AUC, Area under the receiver operating characteristic curve.
TABLE II. Optimal cutoffs to classify subjects at high-risk for developing severe allergic reactions and reacting to a low dose (<_0.1
gs) of peanut protein during oral peanut challenge
Parameters
Severe versus nonsevere allergic reactions Threshold <_0.1 g vs >0.1 g of peanut protein
Cutoff Sensitivity Specificity PPV NPV Cutoff Sensitivity Specificity PPV NPV
BAT (% of CD631
basophils)
48 100 (100-100) 97 (95-98) 41 (32-60) 100 (100-100) 1.7 95 (89-100) 91 (86-96) 43 (35-62) 100 (99-100)
Ara h 2–specific
IgE (kU/L)
1.4 100 (100-100) 93 (91-98) 22 (18-48) 100 (100-100) 0.1 97 (90-100) 89 (87-95) 38 (34-57) 100 (99-100)
Peanut-specific
IgE (kU/L)
5 100 (100-100) 90 (87-98) 18 (15-48) 100 (100-100) 0.4 95 (88 -100) 79 (76-86) 25 (23-34) 100 (99-100)
Peanut-specific
IgG4 (mg/L)
175 75 (17-100) 46 (30-99) 3 (2-29) 99 (98-100) 75 82 (67-89) 34 (32-45) 8 (8-10) 96 (94-98)
IgG4/IgE ratio 1.6 100 (92-100) 88 (86-98) 16 (14-60) 100 (100-100) 2.1 91 (86-100) 87 (78-92) 35 (25-46) 99 (99-100)
Peanut SPT (mm) 8 100 (100-100) 92 (89-94) 21 (17-27) 100 (100-100) 6 98 (97-100) 95 (91-96) 59 (45-66) 100 (100-100)
Severity was assessed according to the Common Terminology Criteria for Adverse Events scale.18 Optimal cutoffs were determined on the basis of the Youden index, which is the
distance between the point of inflection of the receiver operator characteristic curve and the reference line (see the Methods section in this article’s Online Repository at
www.jacionline.org). Sensitivity, specificity, PPV, and NPV with 95% CIs are indicated for each cutoff.
NPV, Negative predictive value; PPV, positive predictive value.
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FIG 3. Threshold dose of peanut protein. Extinction curve relating the cumulative peanut threshold dose
with the proportion of activated basophils following peanut stimulation (A), showing the estimated mean
(and 95% confidence band) cumulative amount of peanut tolerated as a function of BAT measurement,
and receiver operator characteristic curve for different biomarkers for predicting a threshold less than
0.1 g of peanut protein (B). AUC, Area under the receiver operating characteristic curve.
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FIG 4. Nomogram for predicting reaction severity using the BAT, the SPT, and level of Ara h 2–specific
IgE (A) and nomogram for predicting cumulative dose threshold using the BAT, the SPT, level of
Ara h 2–specific IgE, and IgG4/IgE ratio (B) on the basis of the LEAP and PAS studies when subjects were
approximately 5 years of age. Predictions from the models can be made in a clinical setting by simply add-
ing up points earned from each of the variable axes and then using that total to read estimated probabilities
from the probability axes. A, For example, if we encounter a participant with an rArah h 2 level of of 1.5, a
peanut SPT result of 8, and a BAT result of 53, we first find the value 1.5 along the axis associated with rArah
h 2 (second from the top) and read vertically up to the corresponding point along the top Points axis (blue
arrow). Similarly, we find the value 8 along the Peanut SPT axis and follow vertically to the Points axis to find
that a Peanut SPT result of 8 earns about 76 points (red arrow). Similarly, a BAT value of 53 earns about 78
points (green arrow). Totaling the points earned from each variable gives 155 points for this participant. We
find this total points value on the Total Points axis (fourth from the bottom) and imagine a vertical line ex-
tending down from that point intersecting each of the probability axes. These points of intersection are the
predicted probabilities of falling into each of the severity categories. Given the values for the aforemen-
tioned hypothetical participant, we estimate less than a 10% chance of having a severe reaction, a 90%
chance of having a moderate reaction, and less than a 10% chance of no reaction. B, For example, if we sup-
pose that in addition to the biomarker values seen in (A), the participant has a log10-IgG4/IgE ratio to peanut
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TABLE III. Model performance measures for reaction severity
Model C-Index
Absolute calibration error
Moderate or higher Severe/life-threatening
Mean 90th percentile Mean 90th percentile
Multivariable (BAT) 0.991 0.5 0.9 0.3 0.3
Multivariable (no BAT) 0.985 0.3 1 0.5 0.3
SPT 0.985 0.5 1.6 0.5 0.6
Ara h 2–specific IgE 0.951 4.1 7.3 0.3 0.1
BAT 0.951 1.6 4 0.3 0.2
IgE to peanut 0.914 4.4 14.3 0.6 1.7
IgG4 to peanut 0.563 1.1 1.7 0.4 1
The C-index measures the model’s rank discrimination (ie, the ability of the model to correctly rank subjects), with 1 being perfect discrimination and 0.5 indicating a coin toss
model. The calibration error measures how far apart in percentage points model-based predictions are from true predictions, as in a calibration curve, for each ordinal model cut
point. The mean absolute calibration error is the absolute prediction error averaged across all predictions made, with an analogous definition for the 90th percentile of absolute
prediction error. In each case, the smaller the error, the better.
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3%, and 16% participants in the LEAP, LEAP-On, and PAS
studies had severe reactions, respectively. There was some degree
of concordance with other severity scales (Kendall t5 0.12-0.64
[see Fig E2 in this article’s Online Repository at www.jacionline.
org]).The BAT confirmed its high specificity to diagnose
PA
Basophil activation to peanut was higher in subjects with
PA than in subjects without PA (Fig 1 and see Fig E3 in this
article’s Online Repository at www.jacionline.org), with risk
of reaction at the 75th percentile of the BAT results being
3.85-fold higher than the 25th percentile of the BAT results
(hazard ratio 5 3.85; 95% CI, 3.2-4.7; P < .001). Using data
from participants in the LEAP and PAS studies, we applied
the optimal diagnostic cutoff previously identified for BAT to
peanut11 (ie, 4.78% CD631 basophils for average BAT result
at 10 and 100 ng/mL of peanut extract), which had 74.7%
sensitivity, 98.7% specificity, a 95.4% negative predictive
value, a 91.5% positive predictive value, and 57.8 and 0.3
positive and negative likelihood ratios, respectively, to diag-
nose PA. Basophil activation in response to anti-IgE,
anti-FcεRI, and fMLP was similar across allergic status
(see Fig E4 in this article’s Online Repository at www.
jacionline.org).The BAT and other tests identified participants with
severe or life-threatening allergic reactions during
oral peanut challenges with high accuracy
Participants with severe or life-threatening reactions during
OFC had higher proportions of activated basophils in response to
peanut than did participants with mild or moderate reactions
(Fig 2, A and see Table E9 in this article’s Online Repository atof 1.6, the nomogram could be used if we wanted to
probabilities of having mean cumulative doses great
With a BAT value of 53 we accrue about 62 points, and
a peanut wheal of 8 gives about 85 points, and an IgG4
then has about 247 points in total, which gives an estim
of peanut, a 45% chance of tolerating more than 0.1 g
more than 9.35 g of peanut. In fact, this individual had
cebo-controlled food challenge (DBPCFC) and tolerat
=
www.jacionline.org). Basophil activation in response to anti-
FcεRI and anti-IgE (but not fMLP) was higher for severe reactors
than for nonsevere reactors (see Fig E4 in this article’s Online
Repository at www.jacionline.org). Fig 2, B-D illustrate the re-
sults for the other biomarkers according to allergic status, high-
lighting participants with severe or life-threatening reactions.
The BAT showed high accuracy in identifying subjects with
severe or life-threatening allergic reactions according to the
CommonTerminologyCriteria for Adverse Events severity score,
and it was the single biomarker with the largest area under the
receiver operator characteristic curve (0.985 [see Fig 2, B]) and
therefore with the best discriminatory ability. The optimal cutoff
for the BAT had 100% sensitivity and 97% specificity to identify
high-risk subjects (Table II). The SPT, Ara h 2–specific IgE level,
peanut-specific IgE level, and IgG4/IgE ratio all had 100% sensi-
tivity but lower specificity to predict severity (92%, 93%, 90%,
and 88%, respectively). The performance of various tests to iden-
tify severe reactors was similar with use of the different systems to
classify the severity of allergic reactions (Fig 2, B and see Fig E5,
B and Table E10 in this article’s Online Repository at www.
jacionline.org). A multivariable model of reaction severity sug-
gests that after adjustment for the SPT result and level of Ara h
2–specific IgE, the BAT still contributes significantly to the pre-
diction of reaction severity (see Table E11 in this article’s Online
Repository at www.jacionline.org).The SPT and BAT were the best predictors of the
threshold dose of reactivity to peanut during oral
challenges
Participants reacting clinically to lower doses of peanut protein
had higher proportions of activated basophils (Fig 3 and see Figs
E6-E9 in this article’s Online Repository at www.jacionline.org)
and higher basophil sensitivity, as measured by CD-sens (see
Fig E8). There was no association between lower threshold
dose and basophil activation to the positive controls fMLP,estimate the mean cumulative tolerated dose, or the
er than 0.1 g or 9.35 g given these biomarker values.
with an Ara h 2 value of 1.5 we accrue about 5 points;
/IgE ratio of 1.6 gives about 95 points. This individual
atedmean cumulative tolerated dose of less than 1 g
of peanut, and less than a 10% chance of tolerating
a severe reaction during the peanut double-blind pla-
ed 0 g of peanut.
TABLE IV. Model performance measures for cumulative dose threshold
Model C-Index
Absolute calibration error
0.1 g 5.0 g 9.35 g
Mean 90th percentile Mean 90th percentile Mean 90th percentile
Multivariable 0.981 1.6 5.6 0.8 2.7 0.3 0.2
Multivariable (no BAT) 0.980 2.2 5.1 1 3 0.7 1.2
SPT 0.972 1.4 8.9 0.8 3.2 0.6 2
BAT 0.938 1.8 7.8 1 2 0.9 2.8
Ara h 2–specific IgE 0.938 3.6 13.4 6.2 9.6 6.9 12.6
IgG4/IgE ratio to peanut (log 10) 0.932 3.1 8 3.6 6.4 2.1 2.8
IgE to peanut 0.899 4 10.1 6 16.8 6.6 20.7
IgG4 to peanut 0.565 1.7 2.1 2.6 4.8 3 4.2
The C-index measures the model’s rank discrimination (ie, the ability of the model to correctly rank subjects), with 1 being perfect discrimination and 0.5 indicating a coin toss
model. The calibration error measures how far apart in percentage points model-based predictions are from true predictions, as in a calibration curve, for each ordinal model cut
point. The mean absolute calibration error is the absolute prediction error averaged across all predictions made, with an analogous definition for the 90th percentile of absolute
prediction error. In each case, the smaller the error, the better.
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participants who remain reaction-free as a function of cumulative
peanut dose and reinforces the concept that the higher the propor-
tion of activated basophils, the lower the dose of peanut protein to
which patients react during OFC. With use of the receiver oper-
ator characteristic curve analyses, the optimal cutoffs for the
SPT, level of Ara h 2–specific IgE, and IgG4/IgE ratios also had
a very good performance in identifying patients with a cumulative
threshold dose of 0.1 g or lower (Table II).Models combining different biomarkers to predict
severity and threshold dose of allergic reactions
during oral peanut challenges
We designed multivariate models combining different
parameters to determine the risk of a severe reaction and, with
the application of our findings to routine clinical practice in
mind, we used these models to generate nomograms (Fig 4A
and see Fig E10, A-H in this article’s Online Repository at
www.jacionline.org). We performed internal validation of these
models by using the bootstrap to correct for the bias of using
the same data to fit and validate the model. Although the
performance of both multivariate models was good (Table III),
on the basis of calibration, the model including the BAT more
accurately predicted the probability of severe or life-threatening
reactions than did either the model without the BAT or the
individual tests.
A multivariable model for threshold built using the best
predictors for cumulative threshold dose and including the BAT
(the SPT, the BAT, level of Ara h 2–specific IgE, level of
peanut-specific IgE, and IgG4/IgE ratio) was superior to the
model without BATand outperformed models based on any of the
predictors individually (Table IV). The nomogram in Fig 4, B
depicts this multivariable model and can be used to make
predictions of threshold of future reactions during PA testing.
A similar nomogram without BAT is shown in Fig E11 (in this
article’s Online Repository at www.jacionline.org).
Internal validation reflects mostly the performance of the
model within a population similar to the population of the present
study, and external validation is important to assess the model in
more general settings. External validation of the severity and the
threshold models was performed by using an independent
cohort recruited from 2 specialized pediatric allergy outpatientclinics in London (see Table E2). Although this data set was
limited by not including severe cases, the model did
accurately predict those without allergy and mild or moderate
reactions. For more details, see the Results section in the Online
Repository, Table E12 and Figs E12-E14 in this article’s Online
Repository at www.jacionline.org.
We observed a relationship between clinical severity and
cumulative threshold dose in patients with PA: the lower the
cumulative dose of peanut protein tolerated, the greater
the severity of allergic reactions to peanut during
incremental peanut challenge (Fig 5). A test of the association
between the risk of having a reaction during OFC and
percentage of CD631 basophils was found to be significant
(P < .001).DISCUSSION
The OFC is the criterion standard to diagnose PA, to confirm
eligibility for clinical trials, and to assess the response to
treatments of patients who are known to be allergic. Although
OFC is generally safe, the severity of allergic reactions is
unpredictable and allergic symptoms can cause significant
discomfort and anxiety to patients and families.1,2 Furthermore,
OFCs are costly and time-consuming, and they require a lengthy
visit that may be obviated by objective, safer, cheaper, and more
convenient biomarkers. Herein, we tested a large number of very
well-characterized subjects who participated in the LEAP study
and associated studies, and we confirmed that the BAT is an excel-
lent biomarker of PA and that the BAT and other biomarkers are
able to identify patients at risk of reacting to small amounts of
peanut protein and developing severe symptoms during peanut
OFC. The multivariate model that combines various biomarkers
can be computed by using nomograms to identify individuals at
high-risk of a severe or life-threatening reaction or with a low
threshold of reactivity during OFC in clinical practice. There
are very few data in the literature combining different biomarkers
to determine diagnostic accuracy, and we have demonstrated in
this article that a multivariate model predicts severity and
threshold. We have also demonstrated an inverse correlation be-
tween threshold and severity of allergic reactions to peanut.
We have shown, for the first time, that the SPT, specific IgE
level, level of Ara h 2–specific IgE, and BAT are predictors of
severity of allergic reactions during OFC. The optimal cutoffs for
FIG 5. Relationship between severity and threshold of allergic reactions to peanut. Points represent
individual subjects submitted to either double-blind placebo-controlled (blue points) or open (red points)
peanut challenges in the LEAP studies. The Spearman rank correlation between cumulative tolerated
dose and severity of Common Terminology Criteria for Adverse Events (CTCAE)-graded reactions is
–0.96 (P < .001) at 60 months and –0.94 (P < .001) at 72 months. When these correlations were computed,
open challenges not ending in a reaction were given an imputed tolerated cumulative dose of 9.35 g.
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meaning that all subjects with severe reactions had results for
these tests that were above the defined cutoff. Furthermore, this is
the largest cohort tested with the BAT to peanut by using amethod
that was previously validated.11 Study participants were very well
characterized with a rigorous methodology.15,16 The BAT proved
to be an accurate diagnostic test that is able to confirm PA with
high specificity, which is in agreement with our previous find-
ings.11 Being able to identify patients with PA who are at risk
of reacting to a low dose of the allergen and/or at risk of devel-
oping life-threatening reactions can improve current management
of patients with PA. Previous studies, including our own peanut
study using the exact same BAT methodology,9 have shown a
direct correlation between the severity of symptoms and basophil
activation and an inverse correlation between the threshold of
reactivity and basophil activation.9,12,13 More recently, another
study of patients undergoing OFC to peanut identified the BAT
as the best biomarker for severity of allergic symptoms22 when
using the same BAT parameter that we had previously chosen
as the preferred outcome for the BAT.9 In the present study, we
also assessed basophil sensitivity as expressed by CD-sens, which
previously was the marker that best reflected low threshold dose,
and we found that basophils of patients reacting at lower doses of
peanut protein in the OFC reacted to lower concentrations of pea-
nut extract in vitro, thus displaying a higher CD-sens. Of note, the
associations between SPT and threshold and between SPT and
severity may be biased toward a stronger association, given that
the clinician knows the results of the SPT before doing the chal-
lenge. Conversely, because the clinician is not aware of the BATresults, the BATmay have less of an intrinsic bias andmay consti-
tute a more robust biomarker of severity and threshold compared
with, for instance, the SPT result, which was known to the clinical
team performing the OFC.
The observation that a higher proportion of activated baso-
phils is associated with more severe reactions and a lower
threshold raises the question as to whether severity is linked to
threshold. Although clinically this association is difficult to
establish owing to the ethical constraints of continuing OFC
after an allergic reaction has started, we have previously shown
that in vitro BAT markers of severity and threshold are strongly
correlated. This strong correlation is probably due to the ability
to stimulate basophils in vitro with higher concentrations of
allergen than are possible in vivo during OFC for ethical reasons.
In the LEAP study protocol, OFC was started at a relatively high
dose of peanut protein (0.1 g in most patients and 0.033 g in
high-risk patients15,23) because this was a diagnostic OFC,
whereas most OFCs start with less than 10 mg of peanut protein
and, according to other threshold studies, a dose of 100 mg ap-
proaches the eliciting dose for 30% to 50% of the population
with PA; thus, the LEAP study is poorly designed to look at
threshold. However, because OFC started at a relatively high
dose, we were able to see a strong correlation between threshold
and severity that would otherwise not have been possible, as the
OFC would have been stopped at the first signs of an allergic re-
action at lower doses. The fact that BAT in this study is related to
both severity and threshold further indirectly supports a link be-
tween low threshold and increasing severity of allergic
reactions.
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the allergen does not necessarily mean that the patient will have a
severe allergic reaction when accidentally exposed to the allergen,
but it allows identification of high-risk patients who deserve a
closer follow-up. This is in line with the findings of other studies
and the notion that severity of allergic reactions depends on a
multitude of factors,24 of which the effector cell biology is only
one. The fact that the basophil response to IgE-mediated positive
controls (but not to the non–IgE-mediated positive control
fMLP) was higher in severe reactors than in patients with mild or
moderate reactions may suggest that differences intrinsic to the
IgE-mediated pathway in basophil effector cells can influence the
severity of symptoms. The same was not observed for threshold
dose or for allergic status to peanut.
Previous studies investigating the SPT and testing of specific
IgE as biomarkers for severity showed conflicting results—some
with positive findings5,6,9,25-30 and others with negative find-
ings,7,8,31-35 possibly because of differences in study design, pa-
tients included, and OFC protocols. In contrast, in our study,
tests other than the BAT, such as the SPT, Ara h 2–specific IgE,
peanut-specific IgE, and IgG4/IgE ratios, performed well in iden-
tifying severe reactors. For instance, an SPT result of 8 mm or
larger can be useful clinically to identify patients at greater risk.
The SPT was in fact the best biomarker for threshold followed
by BAT. However, better than any individual test were the multi-
variate models, as shown by the higher C-value. We would like to
underscore that statistically speaking, improving on an already
high C-index is ‘‘more significant’’ than the same level of
improvement of a lower C-index. Multivariate models take into
account the correlation between metrics, and this adds robustness
to the predictions of individual tests. We included the results of
tests in a multivariate model to generate user-friendly nomograms
to predict the probability of a serious adverse event during peanut
OFC for a given patient. This may be different from allergic
reactions in the community, where additional factors that are
controlled for in the context of OFC can contribute to the outcome
(eg, uncontrolled asthma, concomitant infection, and other cofac-
tors)5,36 The nomograms can be very useful clinically, with the
ability to identify high-risk patients who may benefit from a
different OFC protocol, starting with lower doses with more care-
ful clinical monitoring (eg, cannulation before the start of OFC,
higher clinician-to-patient ratio during OFC) or determining
when OFC should be dispensed with. Instead, confirmation of
PA could be done with an in vitro test such as the BAT or with a
combination of tests using the nomogram. Because of the limita-
tions of the external validation cohort used in the present study,
further rigorous external validation is needed before applying
these results more broadly, namely, with other food allergens
and in other patient populations.
A proportion of participants could not be tested with the BAT
for logistic reasons, namely, failure to collect blood, appoint-
ments too late in the day, or too many appointments per day to
allow for performance of the BAT in a timely fashion. This
limitation highlights the need to simplify the BAT procedure and
have an organized system to overcome these barriers in clinical
practice, should the BAT be used as a biomarker in a real-life
scenario. The differences observed between patients who were
and were not tested with the BAT reflect the fact that tested
patients were more likely to be allergic to peanut. As patients
without allergy do not ever have a positive response to allergen onthe BAT, we believe that this potential bias has not affected the
results but rather has granted the ability to capture a high-risk
population.
In all, 14% percent of samples were not considered in the
analyses because of nonresponder basophils, which is a known
limitation of BAT. However, nonresponders would not lead to
misdiagnosis of high-risk patients, as these patients required an
OFC to confirm or exclude PA, and thus, we would not exclude
allergy on the basis of nonresponder status. In clinical practice,
there are patients for whom we do not have results for the other
tests. For instance, a significant proportion of children do not react
on the SPT, when during the pollen season, they cannot stop
taking antihistamines, and in such situations, the BAT is
particularly useful because it is not affected by antihistamines.37
The nonresponder status was not consistent over time, with some
participants having nonresponder basophils at 1 time point
(LEAP/LEAP-On studies) and not the other, which is in line
with experimental data showing that the nonresponder status re-
sults from transient changes in cell signaling proteins and can
be reversed in different culturing conditions, namely, in the pres-
ence of IL-3.38,39 The model without the BAT could be used to
identify patients at risk of severe reactions and low threshold, in
the case of nonresponders.
In summary, by using a large cohort of well-characterized
patients, we confirmed that the BAT is a biomarker of PA and of
the severity and threshold of allergic reactions to peanut during
OFC. All of the other markers had a very good sensitivity but
lower specificity to predict severity, whereas the SPTwas a better
biomarker for threshold. The best predictive approach both for
severity and for threshold was to combine tests in a multivariate
model. By using novel models that integrate various biomarkers,
we are able to generate nomograms that could be used in clinical
practice to identify patients with allergy who are at higher risk of
experiencing severe allergic reactions or of reacting to a low dose
of peanut protein and offer them a more personalized manage-
ment plan and follow-up.
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Key messages
d The BATwas useful to diagnose PA and to predict severity
and threshold of reactivity to peanut in the LEAP studies.
d The SPTand level of Ara h 2–specific IgE were also useful
biomarkers of severity and threshold in the LEAP
cohorts.
d Multivariate models combining basophil activation with
other tests using a nomogram identified children with se-
vere allergic reactions and low threshold of reactivity dur-
ing oral peanut challenges.
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